Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients

Cancer Investigation

Volumn 17, Issue 5, 1999, Pages 309-313

  Sandoval, Claudio ^a   Corbi, Dominic ^b   Strobino, Barbara ^a   Ozkaynak, M Fevzi ^a   Tugal, Oya ^a   Jayabose, Somasundaram ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; ETOPOSIDE; ONDANSETRON;

ADOLESCENT; ADULT; ANTIEMETIC ACTIVITY; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LYMPHOMA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; VOMITING;

EID: 0032999786     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909909032871     Document Type: Article

References (31)

1. Billet AM, Sallen SE: Management of nausea and vomiting. In: Principles and Practice of Pediatric Oncology, 2nd ed., edited by PA Pizzo, DG Poplack, Philadelphia, Lippincott, 1993, pp. 1051-1057.
2. Brunton LL: Agents affecting gastrointestinal water flux and motility; emesis and antiemetics; bile acids and pancreatic enzymes. In: The Pharmacologic Basis of Therapeutics, 9th ed., edited by JG Hardman, LE Limbird, PB Molinoff, et al, New York, McGraw-Hill, 1996, pp. 928-934.
3. Miner WD, Sanger GJ, Turner DH: Evidence that 5-hydroxytryptamine receptors mediate cytotoxic drug and radiation-induced emesis. Br J Cancer 56:159-162, 1987.
4. Cubeddu LX, Hoffman IS, Fuenmayor NT, et al: Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 66: 193-203, 1992.
5. Cubeddu LX, Hoffman IS, Fuenmayor NT, et al: Antagonism of serotonin S3 receptors with ondansetron prevents nausea and vomiting induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol 8:1721-1727, 1990.
6. Cubeddu LX, Hoffman IS, Fuenmayor NT, et al: Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin induced nausea and emesis. N Engl J Med 322:810-816, 1990.
7. Italian Group for Antiemetic Research. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 11:2396-2404, 1993.
8. Navari RM, Province WS, Perrine GM, et al: Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemelics in control of acute nausea induced by cisplatin chemotherapy. Cancer 72:583-586, 1993.
9. Roila F: Ondansetron plus dexamethasone compared to the standard metoclopramide combination. Oncology 50:163-167, 1993.
10. Hainsworth J, Harvey W, Pendergrass K, et al: A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721-728, 1991.
11. Dick GS, Meller ST, Pinkerton CR: Randomized comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Arch Dis Child 73:243-245, 1995.
12. Seynaeve D, Schuller J, Buser K, et al: Comparison of the antiemetic efficacy of different doses of ondansetron given as either a continuous infusion or a single intravenous dose in acute cisplatin-induced emesis. A multicenter, double-blind, randomized parallel group study. Br J Cancer 66:192-197, 1991.
13. Beck TM, Hesketh PH, Madajewicz S, et al: Stratified, randomized double-blind comparison of intravenous ondansetron administered as a multi-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969-1975, 1992.
14. Dicato MA, Kaasa S, Campora E, et al: Efficacy of twice-daily versus three times daily oral ondansetron in the prevention of chemotherapy-induced emesis: a randomized, single-blind multicenter study. J Clin Oncol R Coll Radiol 4:275-279, 1992.
15. Grunberg SM, Lane M, Lester EP, et al: Randomized, double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Pharmacol 32:268-272, 1993.
16. Isavaris N, Mylonakis N, Bacoyiannis C, et al: Efficacy of ondansetron treatment with different timing schedules: a randomized double-blind study. Oncology 52:315-318, 1995.
17. Holdsworth MT, Raisch DW, Duncan MH, et al: Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. Ann Pharmacother 29:16-21, 1995.
18. Cohen LJ, Zehavi N, Buchwald I, et al: Oral ondansetron- an effective ambulatory complement to intravenous ondansetron in the control of chemotherapy-induced nausea and vomiting in children. Pediatr Hematol Oncol 12:67-72, 1995.
19. Stevens R, Voltan B, Lane R, et al: A randomized study of ondansetron syrup in children: evaluation of taste acceptability and tolerance. Pediatr Hematol Oncol 13:199-202, 1996.
20. Bryson JC: Clinical safety of ondansetron. Semin Oncol 19(Suppl 15):26-32, 1992.
21. Kossey JL, Kwok KK: Anaphylactoid reactions associated with ondansetron. Ann Pharmacother 28:1029-1030, 1994.
22. Kataja V, de Bruijn KM: Hypersensitivity reactions associated with 5-hydroxytryptamine (3)-receptor antagonist: a class effect? Lancet 347:584-585, 1996.
23. Halperin JR, Murphy B: Extrapyramidal reaction to ondansetron. Cancer 69:1275, 1992.
24. Gracia-del-Muro X, Cardenal F, Ferrer, P: Extrapyramidal reaction associated with ondansetron. Eur J Cancer 29A:288, 1993.
25. Hesketh PJ, Kris MG, Grunberg SM, et al: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109, 1997.
26. Balis FM, Holcenberg JS, Poplack DG: General principles of chemotherapy. In: Principles and Practice of Pediatric Oncology, 2nd ed., edited by PA Pizzo, DG Poplack, Philadelphia, Lippincott, 1993, p. 235.
27. Pritchard JF, Bryson JC, Kernodle AE, et al: Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy volunteers. Clin Pharmacol Ther 51:51-55, 1992.
28. Roila F, Tonato M, Gognetti F, et al: Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675-678, 1991.
29. Smith DB, Newlands ES, Rustin GJ, et al: Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 338: 487-490, 1991.
30. Joss RA, Bacchi M, Buser K, et al: Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naïve and previously treated patients. Swiss Group for Clinical Cancer Research. Ann Oncol 5:253-258, 1994.
31. Alvarez O, Freeman A, Bedros A, et al: Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 17:145-150, 1995.